Portfolio / Alveron

Alveron.gif

Company:
ALVERON

Fund:
II

Status:
Active

Technology:
Therapeutics

Website

05.jpg

Team member:
Michel Briejer

Alveron Pharma is developing a unique coagulation platform technology with the world’s first cyclodextrin-based anticoagulant reversal drug.

Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic anti-bleeding agents, and our lead program is focused on developing a truly universal anticoagulant reversal agent.